Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Varicella zoster virus infections increase the risk of disease flares in patients with SLE: a matched cohort study.

Sun F, Chen Y, Wu W, Guo L, Xu W, Chen J, Sun S, Li J, Chen Z, Gu L, Wang X, Li T, Ye S.

Lupus Sci Med. 2019 Jul 29;6(1):e000339. doi: 10.1136/lupus-2019-000339. eCollection 2019.

2.

Longitudinal analysis of varicella-zoster virus-specific antibodies in systemic lupus erythematosus: No association with subclinical viral reactivations or lupus disease activity.

Rondaan C, van Leer CC, van Assen S, Bootsma H, de Leeuw K, Arends S, Bos NA, Westra J.

Lupus. 2018 Jul;27(8):1271-1278. doi: 10.1177/0961203318770535. Epub 2018 Apr 18.

4.

Herpes zoster vaccination in SLE: a pilot study of immunogenicity.

Guthridge JM, Cogman A, Merrill JT, Macwana S, Bean KM, Powe T, Roberts V, James JA, Chakravarty EF.

J Rheumatol. 2013 Nov;40(11):1875-80. doi: 10.3899/jrheum.130170. Epub 2013 Sep 15.

5.

Microbiological and immunological profile of patients with severe lupus flares related to bloodstream infections: a retrospective cohort study.

Torres-Ruiz J, Barrera-Vargas A, Ortiz-Hernández R, Alcocer-Varela J, Ponce-de-León A, Gómez-Martín D.

Lupus. 2018 Feb;27(2):312-318. doi: 10.1177/0961203317720527. Epub 2017 Jul 12.

PMID:
28699377
6.

Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus.

Barbosa CM, Terreri MT, Rosário PO, de Moraes-Pinto MI, Silva CA, Hilário MO.

Clin Exp Rheumatol. 2012 Sep-Oct;30(5):791-8. Epub 2012 Oct 17.

PMID:
22935227
7.

Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study.

Inês L, Duarte C, Silva RS, Teixeira AS, Fonseca FP, da Silva JA.

Rheumatology (Oxford). 2014 Jan;53(1):85-9. doi: 10.1093/rheumatology/ket322. Epub 2013 Sep 24.

PMID:
24067885
8.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995.

9.

Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study.

Závada J, Uher M, Svobodová R, Olejárová M, Hušáková M, Ciferská H, Hulejová H, Tomčík M, Šenolt L, Vencovský J.

Arthritis Res Ther. 2015 Nov 25;17:341. doi: 10.1186/s13075-015-0862-4.

10.

Predicting flares in patients with stable systemic lupus erythematosus.

Cho J, Lahiri M, Teoh LK, Dhanasekaran P, Cheung PP, Lateef A.

Semin Arthritis Rheum. 2019 Aug;49(1):91-97. doi: 10.1016/j.semarthrit.2019.01.001. Epub 2019 Jan 5.

PMID:
30660381
11.

A surge in anti-dsDNA titer predicts a severe lupus flare within six months.

Pan N, Amigues I, Lyman S, Duculan R, Aziz F, Crow MK, Kirou KA.

Lupus. 2014 Mar;23(3):293-8. doi: 10.1177/0961203313515763. Epub 2013 Dec 6.

PMID:
24316605
12.

Pathways of impending disease flare in African-American systemic lupus erythematosus patients.

Munroe ME, Vista ES, Merrill JT, Guthridge JM, Roberts VC, James JA.

J Autoimmun. 2017 Mar;78:70-78. doi: 10.1016/j.jaut.2016.12.005. Epub 2017 Feb 2.

13.
14.

Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus.

Park HB, Kim KC, Park JH, Kang TY, Lee HS, Kim TH, Jun JB, Bae SC, Yoo DH, Craft J, Jung S.

J Rheumatol. 2004 Nov;31(11):2151-5.

PMID:
15517626
15.

How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.

Thanou A, Chakravarty E, James JA, Merrill JT.

Rheumatology (Oxford). 2014 Dec;53(12):2175-81. doi: 10.1093/rheumatology/keu153. Epub 2014 Apr 11.

16.

Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases.

Rondaan C, de Haan A, Horst G, Hempel JC, van Leer C, Bos NA, van Assen S, Bijl M, Westra J.

Arthritis Rheumatol. 2014 Nov;66(11):3122-8. doi: 10.1002/art.38804.

17.

Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study.

Peng L, Wang Z, Li M, Wang Y, Xu D, Wang Q, Zhang S, Zhao J, Tian X, Zeng X.

Clin Rheumatol. 2017 Dec;36(12):2727-2732. doi: 10.1007/s10067-017-3842-z. Epub 2017 Sep 19.

PMID:
28929239
18.

Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis.

Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ.

Arthritis Care Res (Hoboken). 2016 Sep;68(9):1295-302. doi: 10.1002/acr.22837. Epub 2016 Jul 27.

19.

Flares in pediatric systemic lupus erythematosus.

Weiss JE, Sison CP, Ilowite NT, Gottlieb BS, Eberhard BA.

J Rheumatol. 2007 Jun;34(6):1341-4. Epub 2007 May 1.

PMID:
17477466
20.

Development and validation of a risk calculator to differentiate flares from infections in systemic lupus erythematosus patients with fever.

Beça S, Rodríguez-Pintó I, Alba MA, Cervera R, Espinosa G.

Autoimmun Rev. 2015 Jul;14(7):586-93. doi: 10.1016/j.autrev.2015.02.005. Epub 2015 Feb 20. Review.

PMID:
25703012

Supplemental Content

Support Center